NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News & Analysis

$70.75
-2.23 (-3.06 %)
(As of 08/23/2019 02:37 AM ET)
Today's Range
$70.68
Now: $70.75
$73.52
50-Day Range
$69.14
MA: $78.01
$88.56
52-Week Range
$64.08
Now: $70.75
$106.80
Volume144,669 shs
Average Volume219,040 shs
Market Capitalization$1.39 billion
P/E Ratio20.33
Dividend YieldN/A
Beta0.98
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$206.63 million
Cash Flow$3.7237 per share
Book Value$22.77 per share

Profitability

Net Income$71.95 million

Miscellaneous

Employees113
Market Cap$1.39 billion
Next Earnings Date11/25/2019 (Estimated)
OptionableOptionable

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.


Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.27. The biotechnology company earned $44.40 million during the quarter, compared to the consensus estimate of $46.98 million. Enanta Pharmaceuticals had a return on equity of 15.16% and a net margin of 29.22%. The firm's quarterly revenue was down 22.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.97 earnings per share. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 25th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

What price target have analysts set for ENTA?

3 brokers have issued twelve-month price targets for Enanta Pharmaceuticals' stock. Their predictions range from $100.00 to $120.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $112.3333 in the next twelve months. This suggests a possible upside of 58.8% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

What is the consensus analysts' recommendation for Enanta Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Enanta Pharmaceuticals.

Has Enanta Pharmaceuticals been receiving favorable news coverage?

Headlines about ENTA stock have been trending positive on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Enanta Pharmaceuticals.

Who are some of Enanta Pharmaceuticals' key competitors?

What other stocks do shareholders of Enanta Pharmaceuticals own?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 63)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.18%), Vanguard Group Inc. (8.24%), Price T Rowe Associates Inc. MD (7.77%), Farallon Capital Management LLC (4.88%), Janus Henderson Group PLC (4.80%) and Janus Henderson Group PLC (4.80%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Which institutional investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Invesco Ltd., Renaissance Technologies LLC, Bank of New York Mellon Corp, First Manhattan Co., Chicago Equity Partners LLC, AQR Capital Management LLC and Trexquant Investment LP. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathalie Adda, Nathaniel S Gardiner, Tim Ocain and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

Which institutional investors are buying Enanta Pharmaceuticals stock?

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, Janus Henderson Group PLC, Janus Henderson Group PLC, Los Angeles Capital Management & Equity Research Inc., Jacobs Levy Equity Management Inc., JPMorgan Chase & Co. and BlackRock Inc.. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $70.75.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.39 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  537
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/23/2019 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel